TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01387282

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anamorelin HCl
Description: Anamorelin HCL 100 mg will be orally administered daily at least 1 hour prior to meal

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets identical in appearance to active tablets; oral administration QD for 12 weeks, at least 1 hour prior to meal before the first meal of the day.
Study: NCT04150991

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fiber intervention
Description: Each subject will supplement his/her normal dietary intake with 35 grams of dietary fiber daily for three consecutive weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo treatment
Description: Each subject will supplement his/her normal dietary intake with an 18.53-g maltodextrin placebo daily for three consecutive weeks.
Study: NCT02806232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biltricide (racemate praziquantel) oral tablets
Description: Biltricide (600 mg tablet) was administered to participants at a dose of 20 mg/kg in Part 1, Cohort 1 and at a dose of 40mg/kg in Part 1, Cohort 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biltricide (racemate praziquantel) oral tablets
Description: Biltricide (600 mg tablet) was administered to participants at a dose of 20 mg/kg in Part 1, Cohort 1 and at a dose of 40mg/kg in Part 1, Cohort 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Racemate Praziquantel ODT
Description: Racemate Praziquantel (PZQ) (150) mg was administered at a dose of 40 mg/kg in Part 1, Cohort 3 and at a dose of 60 mg/kg in Part 1, Cohort 4.
Study: NCT02480595

Intervention type: DEVICE
Intervention: Stent Graft
Description: Endovascular repair of abdominal aortic aneurysm (EVAR)
Study: NCT02573025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-IFN alfa-2a BA-free formulation (Test)
Description: Participants will receive single injection of 180 micrograms (mcg) of PEG-IFN alfa-2a BA-free formulation, subcutaneously via prefilled syringe in either period 1 and 2 (each period having 35 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-IFN alfa-2a BA-free formulation (Test)
Description: Participants will receive single injection of 180 micrograms (mcg) of PEG-IFN alfa-2a BA-free formulation, subcutaneously via prefilled syringe in either period 1 and 2 (each period having 35 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-IFN alfa-2a market formulation (Reference)
Description: Participants will receive single injection of 180 mcg of PEG-IFN alfa-2a market formulation, subcutaneously via prefilled syringe in either period 1 and 2 (each period having 35 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-IFN alfa-2a market formulation (Reference)
Description: Participants will receive single injection of 180 mcg of PEG-IFN alfa-2a market formulation, subcutaneously via prefilled syringe in either period 1 and 2 (each period having 35 days).
Study: NCT02500329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemigliptin
Description: Gemigliptin for 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acarbose
Description: Acarbose for 4 weeks
Study: NCT04185714

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiotaping
Description: Kinesiotaping (KT) is an approach that supports injured muscles and joints and helps relieve pain.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo taping
Description: sham taping
Study: NCT02551523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir
Description: 92 patients will be simplified to once daily dolutegravir monotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care combinational antiretroviral therapy
Study: NCT03782311

Intervention type: BEHAVIORAL
Intervention: motivation and and oral hygiene instructions
Description: Motivation and oral hygiene instructions were received OHSE-high and OHSE-low groups. After showing the modified-Bass tooth brushing technique and interdental cleaning on the model, patients were followed up while brushing and flossing their teeth to correct misapplications. It was advised to brush teeth twice a day and use the interdental cleaning devices once a day.
Study: NCT00065585

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Accupuncture

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Accupuncture

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Accupuncture
Study: NCT04293263

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 2gether app used by trained personal
Description: each of the elderly in the study group will listen to personalized music twice a week for an hour each time together with a musical partner. Joint listening is performed with 2 pairs of headphones that connect via a splitter to the partner's cell phone. A listening session will take place in a period of 30 minutes and not more than 60 minutes.~Musical partner - A person trained in the program's work plan, which includes contact with empathic listening and the use of a dedicated application developed for it. A musical partner will meet with the same elderly person throughout the study period.~Empathetic listening - a situation in which a person listens to music with another person, while the music enables contact and deepening the connection between people.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: 2gether app used by trained personal
Description: each of the elderly in the study group will listen to personalized music twice a week for an hour each time together with a musical partner. Joint listening is performed with 2 pairs of headphones that connect via a splitter to the partner's cell phone. A listening session will take place in a period of 30 minutes and not more than 60 minutes.~Musical partner - A person trained in the program's work plan, which includes contact with empathic listening and the use of a dedicated application developed for it. A musical partner will meet with the same elderly person throughout the study period.~Empathetic listening - a situation in which a person listens to music with another person, while the music enables contact and deepening the connection between people.
Study: NCT03013088

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CTO Crossing
Description: With confirmation that the target vessel is completely occluded by the target CTO lesion, the operator shall initially attempt crossing the proximal end of the target CTO lesion by advancing ShockWireTM device ≥ 1cm. The SoundBite Crossing device can be activated as needed to perform the procedure and may be used for the entire length of the lesion(s).
Study: NCT03184584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBI-4050
Description: Four 200 mg capsules (800 mg total) administered orally, once daily
Study: NCT04332510

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intact formula
Description: 600 ml of infant formula with intact protein

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Partially hydrolyzed formula
Description: 600 ml of infant formula with partially hydrolyzed protein

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High protein formula
Description: 600 ml of infant formula with high protein level

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Human breast milk
Description: 600 ml of breast milk, safe for human consumption
Study: NCT00420992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALO-01 (Morphine Sulfate Plus Naltrexone Hydrochloride Extended Release)
Description: capsules, up to 80 mg bid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: capsules, bid
Study: NCT00691938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBH589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBH589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBH589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBH589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBH589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBH589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBH589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Study: NCT01572025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dehydroepiandrosterone
Description: Dehydroepiandrosterone (DHEA)(St Mary's Pharmaceutical Unit Cardiff and Vale) DHEA 75 mg capsule. 1 capsule taken once daily for at least 12 weeks prior commencing ovarian stimulation protocol~: Stimulation protocol standard long down-regulation protocol, using human menopausal gonadotropin (HMG)
Study: NCT02806232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Racemate Praziquantel ODT
Description: Racemate Praziquantel (PZQ) (150) mg was administered at a dose of 40 mg/kg in Part 1, Cohort 3 and at a dose of 60 mg/kg in Part 1, Cohort 4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levo Praziquantel ODT
Description: Levo PZQ (150 mg) was administered at a dose of 30 mg/kg in Part 1 Cohort 5, 45 mg/kg Part 1 Cohort 6, 60 mg/kg Part 1 Cohort 7, 50 mg/kg Part 2 Cohort 8, and 50 mg/kg Part 2 Cohort 9.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levo Praziquantel ODT
Description: Levo PZQ (150 mg) was administered at a dose of 30 mg/kg in Part 1 Cohort 5, 45 mg/kg Part 1 Cohort 6, 60 mg/kg Part 1 Cohort 7, 50 mg/kg Part 2 Cohort 8, and 50 mg/kg Part 2 Cohort 9.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levo Praziquantel ODT
Description: Levo PZQ (150 mg) was administered at a dose of 30 mg/kg in Part 1 Cohort 5, 45 mg/kg Part 1 Cohort 6, 60 mg/kg Part 1 Cohort 7, 50 mg/kg Part 2 Cohort 8, and 50 mg/kg Part 2 Cohort 9.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levo Praziquantel ODT
Description: Levo PZQ (150 mg) was administered at a dose of 30 mg/kg in Part 1 Cohort 5, 45 mg/kg Part 1 Cohort 6, 60 mg/kg Part 1 Cohort 7, 50 mg/kg Part 2 Cohort 8, and 50 mg/kg Part 2 Cohort 9.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levo Praziquantel ODT
Description: Levo PZQ (150 mg) was administered at a dose of 30 mg/kg in Part 1 Cohort 5, 45 mg/kg Part 1 Cohort 6, 60 mg/kg Part 1 Cohort 7, 50 mg/kg Part 2 Cohort 8, and 50 mg/kg Part 2 Cohort 9.
Study: NCT03872037

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Selective removal of carious tissue and restoration with Maxxion
Description: Molars subjected to selective removal and restored with Maxxion

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Molars subjected to selective removal and restored with Ketac Molar Easymix
Study: NCT04812509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MW032
Description: The active ingredient of MW032 is a recombinant human anti-RANKL monoclonal antibody ,subcutaneous injection of 120 mg (1.7ml)every 4 weeks for a maximum of 13 consecutive doses throughout the trial.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xgeva
Description: The active ingredient of Xgeva® is denosumab,subcutaneous injection of 120 mg (1.7ml)every 4 weeks for a maximum of 13 consecutive doses throughout the trial.
Study: NCT05391399

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Interlocking detachable coils system
Description: Mainly used to block or slow blood flow in the peripheral vascular system during embolization procedures.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Interlock Fibered IDC Occlusion System
Description: Mainly used to block or slow blood flow in the peripheral vascular system during embolization procedures.
Study: NCT01438723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: prior to CAGB surgery 3 day treatment with metformin 500 mg three times a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: prior to CABG surgery 3 day treatment with placebo capsules three times a day
Study: NCT02457858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Islet isolation using BMX-010
Description: BMX-010 will be used as a supplement in islet isolation process.
Study: NCT05742581

Intervention type: OTHER
Intervention: Computed Tomography
Description: In our study, computerized tomography of 24 rotator cuff tears (rotator cuff tear group) and 20 Bankart lesions, and no rotator cuff tears (control group) were examined. CSA and AI were measured on three-dimensional glenohumeral joint models obtained by three-dimensional reconstructions of computed tomography examinations.

Intervention type: OTHER
Intervention: Computed Tomography
Description: In our study, computerized tomography of 24 rotator cuff tears (rotator cuff tear group) and 20 Bankart lesions, and no rotator cuff tears (control group) were examined. CSA and AI were measured on three-dimensional glenohumeral joint models obtained by three-dimensional reconstructions of computed tomography examinations.
Study: NCT03475797

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Occipital nerve stimulation
Description: Occipital nerve stimulation with percutaneous or surgical lead

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optimal Medical Management
Description: Optimal Medical Management according to what is done in routine clinical practice : drug, psychobehavioral approach, acupuncture, sophrology, etc.
Study: NCT00892671

Intervention type: OTHER
Intervention: Simulation
Description: simulation of airway management and vascular access
Study: NCT02348645

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal fusion

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal decompression

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal decompression
Study: NCT00890708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voriconazole (therapeutic drug monitoring)
Description: dosage adjustment according to trough level of voriconazole in plasma
Study: NCT04331977

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Maxillary Expansion
Description: 2 appliances to expand the maxillary arch

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Maxillary Expansion
Description: 2 appliances to expand the maxillary arch
Study: NCT02989376

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: After detection of occluded vessels by vascular imaging using carotid duplex ultrasound, digital subtraction angiography is immediately performed before acute endovascular treatment.
Description: When the ratio of the end diastolic velocity in the common carotid arteries is greater than 1.4 or the diastolic flow in the internal carotid artery is not detected by vascular imaging using carotid duplex ultrasound, digital subtraction angiography is immediately performed before acute endovascular treatment. If vessel occlusion is not detected by carotid duplex ultrasound, additional vascular imaging including MR angiography or CT angiography is considered.
Study: NCT01581242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clevudine, Adefovir dipivoxil , Clevudine+Adefovir dipivoxil
Description: Clevudine 20mg qd Days 1; Adefovir dipivoxil 10 mg qd Days 8;Clevudine 20mg +Adefovir dipivoxil 10mg qd Days 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clevudine; Adefovir dipivoxil ,Clevudine +Adefovir dipivoxil
Description: Clevudine 20mg +Adefovir dipivoxil 10mg qd Days 1; Clevudine 20mg qd Days 8; Adefovir dipivoxil 10 mg qd Days 15;
Study: NCT03475797

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Optimal Medical Management
Description: Optimal Medical Management according to what is done in routine clinical practice : drug, psychobehavioral approach, acupuncture, sophrology, etc.
Study: NCT01581242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clevudine,Adefovir dipivoxil ,Clevudine +Adefovir dipivoxil
Description: Adefovir dipivoxil 10 mg qd Days 1;Clevudine 20mg +Adefovir dipivoxil 10mg qd Days 8; Clevudine 20mg qd Days 15
Study: NCT00650299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprazolam Extended-release Tablets 3 mg
Description: 3mg, single dose fed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xanax XR® Tablets 3 mg
Description: 3mg, single dose fed
Study: NCT01572025

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched Placebo containing no active ingredient. 1 capsule taken once daily for at least 12 weeks prior commencing ovarian stimulation protocol~: Stimulation protocol standard long down-regulation protocol, using human menopausal gonadotropin (HMG)
Study: NCT03105284

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Liposuction
Description: Fat harvest by liposuction (Colemans method)
Study: NCT03471663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-0502
Description: oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-0502
Description: oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: palbociclib
Description: standard dose of palbociclib
Study: NCT03163914

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine
Description: Epinephrine infusion rate will adjust 30 ml/h (5µg/ ml )
Study: NCT03425864

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: connective tissue graft
Description: patient will receive immediate implant and connective tissue graft
Study: NCT03778918

Intervention type: OTHER
Intervention: inflammatory bowel disease
Description: blood based biomarkers in IBD such as REG3 alpha, serum calprotectin and hs-CRP

Intervention type: OTHER
Intervention: inflammatory bowel disease
Description: blood based biomarkers in IBD such as REG3 alpha, serum calprotectin and hs-CRP

Intervention type: OTHER
Intervention: IBS or Normal Control
Description: blood based biomarker compared normal control with IBD
Study: NCT03425864

Intervention type: DEVICE
Group type: OTHER
Intervention: immediate implant
Description: patient will receive immediate implant with connective tissue graft.
Study: NCT03778918

Intervention type: OTHER
Intervention: IBS or Normal Control
Description: blood based biomarker compared normal control with IBD
Study: NCT03163914

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine
Description: Norepinephrine infusion rate will adjust 30 ml/h (5µg/ ml )

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine
Description: Phenylephrine infusion rate will adjust 30 ml/h (100µg/ ml )

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: saline infusion will apply till the end of the surgery
Study: NCT03489590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PFP
Description: * Composition: inhaled PFP, a gaseous contrast agent (79% PFP, 21% O2, pre-mixed, medical grade gas)~* Administration: Full-face disposable ventilation mask and a standard Douglas Bag system.~* Dosage: Two controlled breaths of contrast gas followed by a full breath and a 12-second breath-hold and scan for image acquisition.~* Frequency: Repeated 5 times followed by an identical five cycles with room air to ensure PFP gas wash-out has occurred.
Study: NCT02755597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Participants self-administered venetoclax tablets by mouth QD in combination with bortezomib. Venetoclax was to be given before other agents administered on the same day, if applicable. Each venetoclax dose was to be taken all at one time with approximately 240 mL of water within 30 minutes after completion of breakfast or the subject's first meal of the day. Tablets were to be swallowed whole and must not have been broken, chewed, or crushed. On days that pre-dose PK sampling was required, dosing occurred at the clinic to facilitate PK sampling.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bortezomib
Description: Bortezomib (subcutaneous injection \[preferred\] or IV) was given following administration of venetoclax or placebo in Cycles 1 -8 on Days 1, 4, 8 and 11, and for Cycles 9 and beyond, on Days 1, 8, 15 and 22 and was to be administered per the prescribing information. The route of administration was to stay the same during the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib (subcutaneous injection \[preferred\] or IV) was given following administration of venetoclax or placebo in Cycles 1 -8 on Days 1, 4, 8 and 11, and for Cycles 9 and beyond, on Days 1, 8, 15 and 22 and was to be administered per the prescribing information. The route of administration was to stay the same during the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone was to be given orally, administered per the prescribing information, the day of bortezomib dosing and the following day, given the protocol-defined dosing window (bortezomib dosing window is ± 1 day) is maintained. If bortezomib was interrupted or a dose is skipped, dexamethasone was to be administered as scheduled per protocol (unless dexamethasone was interrupted due to toxicity).
Study: NCT03425864

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: immediate implant
Description: patient will receive immediate implant with connective tissue graft.
Study: NCT02755597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone was to be given orally, administered per the prescribing information, the day of bortezomib dosing and the following day, given the protocol-defined dosing window (bortezomib dosing window is ± 1 day) is maintained. If bortezomib was interrupted or a dose is skipped, dexamethasone was to be administered as scheduled per protocol (unless dexamethasone was interrupted due to toxicity).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for venetoclax
Description: Participants self-administered placebo tablets by mouth QD in combination with bortezomib. Placebo was to be given before other agents administered on the same day, if applicable. Each placebo dose was to be taken all at one time with approximately 240 mL of water within 30 minutes after completion of breakfast or the subject's first meal of the day. Tablets were to be swallowed whole and must not have been broken, chewed, or crushed. On days that pre-dose PK sampling was required, dosing occurred at the clinic to facilitate PK sampling.
Study: NCT03629574

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ventilation during cardiopulmonary bypass
Description: Mechanical ventilation during cardiopulmonary bypass